

Christopher E M Griffiths

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/177599/christopher-e-m-griffiths-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

704
papers

41,211
citations

101
h-index

177
g-index

756
ext. papers

47,346
ext. citations

4.7
avg, IF

7.41
L-index

#	Paper	IF	Citations
704	Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis.. <i>Dermatology and Therapy</i> , 2022 , 12, 727	4	3
703	Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. <i>Programme Grants for Applied Research</i> , 2022 , 10, 1-240	1.5	
702	Influence of menopause and hormone replacement therapy on epidermal ageing and skin biomechanical function.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	0
701	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022 , 9, 1-106	1.7	
700	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2129639	10.4	17
699	DIFFERENCES IN CLINICAL FEATURES AND COMORBID BURDEN BETWEEN HLA-C*06:02 CARRIER GROUPS IN MORE THAN 9,000 PEOPLE WITH PSORIASIS. <i>Journal of Investigative Dermatology</i> , 2021	4.3	0
698	Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study. <i>Dermatology and Therapy</i> , 2021 , 12, 81	4	1
697	Does the lifestyle of patients with psoriasis affect their illness?. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021 , 75, 643-654	0.3	
696	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. <i>British Journal of Dermatology</i> , 2021 , 185, 80-90	4	17
695	Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e498-e501	4.6	1
694	Predicting Proteolysis in Complex Proteomes Using Deep Learning. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
693	Inflammaging and the Skin. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1087-1095	4.3	21
692	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. <i>British Journal of Dermatology</i> , 2021 , 185, 935-944	4	10
691	Psoriasis. <i>Lancet, The</i> , 2021 , 397, 1301-1315	40	129
690	Peptide location fingerprinting reveals modification-associated biomarker candidates of ageing in human tissue proteomes. <i>Aging Cell</i> , 2021 , 20, e13355	9.9	1
689	AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1297-1298	2.4	2
688	Immediate global support is needed for Myanmar. <i>British Journal of Dermatology</i> , 2021 , 185, 466-467	4	

687	Development of clinical diagnostic criteria for chronic plaque psoriasis: an international e-Delphi study. <i>British Journal of Dermatology</i> , 2021 , 185, 455-456	4	1
686	AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1293-1294	2.4	
685	Professor Lionel Fry (1933-2021). <i>British Journal of Dermatology</i> , 2021 , 185, 237-238	4	
684	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021 , 39, 467-478	3	2
683	Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e496-e498	4.6	1
682	Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. <i>British Journal of Dermatology</i> , 2021 , 185, 441-443	4	5
681	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021 , 185, 825-835	4	1
680	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase B Trials. <i>Dermatology and Therapy</i> , 2021 , 11, 1357-1372	4	3
679	The incidence of psoriasis in Chile: an analysis of the National Waiting List Repository. <i>Clinical and Experimental Dermatology</i> , 2021 , 46, 1262-1269	1.8	2
678	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021 , 185, 646-648	4	13
677	Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. <i>British Journal of Dermatology</i> , 2021 , 185, 978-987	4	3
676	Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study. <i>PLoS ONE</i> , 2021 , 16, e0254661 ^{3.7}		
675	The art of observation: visual literacy for dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e809-e811	4.6	0
674	Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 123-134 ^{4.6}	4.6	12
673	Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink. <i>British Journal of Dermatology</i> , 2021 , 184, 78-86	4	16
672	Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. <i>British Journal of Dermatology</i> , 2021 , 184, 243-258	4	18
671	Diurnal and seasonal variation in psoriasis symptoms. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e45-e47	4.6	6
670	An evaluation of dermatology patients shielding during the COVID-19 outbreak. <i>Clinical and Experimental Dermatology</i> , 2021 , 46, 193-194	1.8	3

669	Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership. <i>Clinical and Experimental Dermatology</i> , 2021 , 46, 276-285	1.8	0
668	Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 928-937	4.6	1
667	Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 60-71	11.5	77
666	Distinctive clinical and histological characteristics of atrophic and hypertrophic facial photoageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 762-768	4.6	3
665	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2021 , 184, 1047-1058	4	24
664	Implementation of the PsoWell Model for the Management of People with Complex Psoriasis. <i>Acta Dermato-Venereologica</i> , 2021 , 101, adv00445	2.2	1
663	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021 ,	4	3
662	The promise and challenges of cell therapy for psoriasis. <i>British Journal of Dermatology</i> , 2021 , 185, 887-898	4.6	2
661	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2409-2414 ¹	4.6	2414 ¹
660	Psoriasis Prevalence in Adults in the United States. <i>JAMA Dermatology</i> , 2021 , 157, 940-946	5.1	20
659	Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study. <i>British Journal of Dermatology</i> , 2021 , 185, 952-960	4	0
658	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1872-1878	4.3	0
657	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e636-e640	4.6	3
656	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021 , 12, 4741	17.4	1
655	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). <i>British Journal of Dermatology</i> , 2021 ,	4	6
654	Restoration of collagen and elastic fibre networks following treatment of photoaged skin with Serflesse, a novel over-the-counter anti-ageing product. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 36, e43	4.6	
653	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. <i>British Journal of Dermatology</i> , 2021 ,	4	8
652	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021 , 8, 1741-1758	4.4	0

651	Physical activity is important for cardiovascular health and cardiorespiratory fitness in patients with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2021 ,	1.8	1
650	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. <i>JAMA Dermatology</i> , 2021 , 157, 66-73	5.1	5
649	The Future of ESDR. <i>Journal of Investigative Dermatology</i> , 2020 , 140, S192-S193	4.3	
648	The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology. <i>Sleep Medicine</i> , 2020 , 72, 144-149	4.6	0
647	The systemic influence of chronic smoking on skin structure and mechanical function. <i>Journal of Pathology</i> , 2020 , 251, 420-428	9.4	6
646	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374	4.5	28
645	National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. <i>BMJ, The</i> , 2020 , 369, m1590	5.9	127
644	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2020 , 183, 792-794	4	32
643	'Mind the gap': what patients and clinicians believe is 'unknown' about psoriasis. <i>British Journal of Dermatology</i> , 2020 , 183, 399-400	4	0
642	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020 , 183, 294-302	4	44
641	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020 , 10, 431-447	4	21
640	Heterogeneity of fibrillin-rich microfibrils extracted from human skin of diverse ethnicity. <i>Journal of Anatomy</i> , 2020 , 237, 478-486	2.9	6
639	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 619-626	7.1	5
638	What are the barriers to physical activity in patients with chronic plaque psoriasis?. <i>British Journal of Dermatology</i> , 2020 , 183, 1094-1102	4	5
637	The relationship between PASI and DLQI with itch, stress, and depression: Do we need additional decision-making tools in psoriasis?. <i>Dermatologic Therapy</i> , 2020 , 33, e13276	2.2	2
636	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020 , 13, 400-409	4.9	5
635	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1440-1448	4.6	15
634	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020 , 183, 404-406	4	16

633	Proteomic fingerprints of damage in extracellular matrix assemblies. <i>Matrix Biology Plus</i> , 2020 , 5, 100027.1	5.1	9
632	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2129-2137	4.3	4
631	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020 , 21, 158	2.8	5
630	Genetic interaction between placental growth factor and vascular endothelial growth factor A in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2020 , 45, 302-308	1.8	4
629	Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting. <i>Dermatologic Therapy</i> , 2020 , 33, e13166	2.2	3
628	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 936-945	4.5	38
627	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020 , 10, 133-150	4	29
626	The short-term effect of levocetirizine on quality of life, stress, and depression in itchy psoriasis patients. <i>Dermatologic Therapy</i> , 2020 , 33, e13179	2.2	3
625	Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	4
624	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020 , 107, 539-543	11	16
623	Remodelling of fibrillin-rich microfibrils by solar-simulated radiation: impact of skin ethnicity. <i>Photochemical and Photobiological Sciences</i> , 2020 , 19, 1160-1167	4.2	2
622	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. <i>Journal of Dermatological Treatment</i> , 2020 , 1-9	2.8	11
621	The Skin Science Foundation: Promoting Skin Health through Research. <i>Journal of Investigative Dermatology</i> , 2020 , 140, S189-S190	4.3	1
620	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020 , 156, 1216-1222	5.1	5
619	Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. <i>British Journal of Dermatology</i> , 2020 , 183, 128-138	4	18
618	Secukinumab for patients failing previous tumour necrosis factor- α inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020 , 183, 60-70	4	11
617	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 769-778	4.6	18
616	Basal cell carcinoma genetic susceptibility increases the rate of skin ageing: a Mendelian randomization study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 97-100	4.6	3

615	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). <i>British Journal of Dermatology</i> , 2020 , 182, 1158-1166	4	39
614	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019 , 155, 1235-1243	5.1	14
613	Mass spectrometry-based proteomics reveals the distinct nature of the skin proteomes of photoaged compared to intrinsically aged skin. <i>International Journal of Cosmetic Science</i> , 2019 , 41, 118-137	3.7	9
612	Understanding the experience of sleep disturbance in psoriasis: a qualitative exploration using the Common-Sense Model of Self-Regulation. <i>British Journal of Dermatology</i> , 2019 , 180, 1397-1404	4	3
611	Ageing significantly impacts the biomechanical function and structural composition of skin. <i>Experimental Dermatology</i> , 2019 , 28, 981-984	4	25
610	The top 10 research priorities for psoriasis in the U.K.: results of a James Lind Alliance psoriasis Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2019 , 181, 871-873	4	8
609	An art-based visual literacy training course to enhance clinical skills in dermatology trainees. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e310-e312	4.6	5
608	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019 , 181, 1265-1274	4	10
607	Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience. <i>British Journal of Dermatology</i> , 2019 , 181, 599-601	4	2
606	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2019 , 180, 329-337	4	24
605	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 1021-1026	11.5	80
604	Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. <i>British Journal of Dermatology</i> , 2019 , 180, 108-115	4	15
603	Incidence and prevalence of psoriasis in Israel between 2011 and 2017. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 2075-2081	4.6	15
602	Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-analysis. <i>JAMA Dermatology</i> , 2019 , 155, 1390-1403	5.1	40
601	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2120-2130	11.5	63
600	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019 , 180, 1069-1076	4	38
599	Selective proteolysis by matrix metalloproteinases of photo-oxidised dermal extracellular matrix proteins. <i>Cellular Signalling</i> , 2019 , 54, 191-199	4.9	18
598	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 115-123	4.3	32

597	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019 , 180, 894-901	4	6
596	Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2019 , 180, 1348-1351	4	7
595	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019 , 181, 256-264	4	9
594	Aging in Skin of Color: Disruption to Elastic Fiber Organization Is Detrimental to Skin's Biomechanical Function. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 779-788	4.3	25
593	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 70-79.e3	4.5	58
592	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 100-107	4.3	18
591	Aged human skin accumulates mast cells with altered functionality that localize to macrophages and vasoactive intestinal peptide-positive nerve fibres. <i>British Journal of Dermatology</i> , 2019 , 180, 849-858	4	20
590	Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1515-1522	4.6	10
589	Lipidomics for translational skin research: A primer for the uninitiated. <i>Experimental Dermatology</i> , 2018 , 27, 721-728	4	16
588	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10	4.5	105
587	Structural and compositional diversity of fibrillin microfibrils in human tissues. <i>Journal of Biological Chemistry</i> , 2018 , 293, 5117-5133	5.4	33
586	Defining tissue proteomes by systematic literature review. <i>Scientific Reports</i> , 2018 , 8, 546	4.9	7
585	Does message framing affect changes in behavioural intentions in people with psoriasis? A randomized exploratory study examining health risk communication. <i>Psychology, Health and Medicine</i> , 2018 , 23, 763-778	2.1	13
584	A photonumeric scale for the assessment of atrophic facial photodamage. <i>British Journal of Dermatology</i> , 2018 , 178, 1190-1195	4	7
583	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018 , 138, 775-784	4.3	46
582	Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis. <i>Value in Health</i> , 2018 , 21, 1010-1018	3.3	12
581	A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. <i>British Journal of Dermatology</i> , 2018 , 179, 173-181	4	38
580	Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. <i>British Journal of Dermatology</i> , 2018 , 179, 863-871	4	10

579	Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. <i>British Journal of Dermatology</i> , 2018 , 178, 1297-1307	4	5
578	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018 , 154, 581-588	5.1	46
577	Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1523-1529	4.6	12
576	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018 , 138, 534-541	4.3	51
575	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. <i>British Journal of Dermatology</i> , 2018 , 178, 1020-1027	4	35
574	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 120-127	4.6	57
573	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018 , 178, 674-681	4	57
572	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2018 , 178, 132-139	4	40
571	Developing a protocol to identify and prioritize research questions for psoriasis: a James Lind Alliance Priority Setting Partnership. <i>British Journal of Dermatology</i> , 2018 , 178, 1383-1387	4	4
570	Keratinocytes derived from late-onset-psoriasis skin do not impair Langerhans cell migration. <i>British Journal of Dermatology</i> , 2018 , 179, 1208-1209	4	2
569	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. <i>JAMA Dermatology</i> , 2018 , 154, 676-683	5.1	56
568	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 785-794	4.3	32
567	Impaired Langerhans cell migration in psoriasis is due to an altered keratinocyte phenotype induced by interleukin-17. <i>British Journal of Dermatology</i> , 2018 , 178, 1364-1372	4	13
566	Lower levels of interleukin-1 gene expression are associated with impaired Langerhans' cell migration in aged human skin. <i>Immunology</i> , 2018 , 153, 60-70	7.8	15
565	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. <i>European Journal of Dermatology</i> , 2018 , 28, 356-363	0.8	10
564	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018 , 19, 465	2.8	11
563	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. <i>Clinical and Experimental Dermatology</i> , 2018 , 43, 759-765	1.8	2
562	Langerhans cells express human defensin 3: relevance for immunity during skin ageing. <i>British Journal of Dermatology</i> , 2018 , 179, 1170-1171	4	10

561	Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years. <i>Journal of Drugs in Dermatology</i> , 2018 , 17, 826-832 ^{2,2}		26
560	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 405-417	4.5	476
559	Organization of the dermal matrix impacts the biomechanical properties of skin. <i>British Journal of Dermatology</i> , 2017 , 177, 818-827	4	31
558	Psoriasis and Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2017 , 7, 31-41	4	48
557	Functional magnetic resonance imaging in dermatology: The skin, the brain and the invisible. <i>Experimental Dermatology</i> , 2017 , 26, 845-853	4	18
556	Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 273-280	7.1	26
555	'New to me': changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well patient materials mixed-methods feasibility study. <i>British Journal of Dermatology</i> , 2017 , 177, 758-770	4	19
554	The challenges of assessing patients' medication beliefs: a qualitative study. <i>BMC Health Services Research</i> , 2017 , 17, 119	2.9	9
553	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2287-2303	4 ⁰	559
552	The global state of psoriasis disease epidemiology: a workshop report. <i>British Journal of Dermatology</i> , 2017 , 177, e4-e7	4	7 ⁰
551	The association between psoriasis and coeliac disease. <i>British Journal of Dermatology</i> , 2017 , 177, e329-e330		11
550	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1410-1421	4	19
549	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017 , 177, 828-836	4	15
548	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017 , 177, 587-590	4	6
547	A cross-sectional survey of the nature and correlates of sleep disturbance in people with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1052-1059	4	3 ⁰
546	Treatment patterns and outcomes among adults admitted to hospital in the U.K. due to plaque or erythrodermic psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, e52-e54	4	0
545	Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. <i>Psychotherapy and Psychosomatics</i> , 2017 , 86, 260-267	9.4	5 ⁰
544	Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors. <i>British Journal of Dermatology</i> , 2017 , 177, 1766-1767	4	1

543	Alcohol-Related Mortality in Patients With Psoriasis: A Population-Based Cohort Study. <i>JAMA Dermatology</i> , 2017 , 153, 1256-1262	5.1	27
542	Inhibition of IL-17A by secukinumab shows no evidence of increased infections. <i>Clinical and Translational Immunology</i> , 2017 , 6, e152	6.8	54
541	A new in vitro assay to test UVR protection of dermal extracellular matrix components by a flat spectrum sunscreen. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017 , 175, 58-64	6.7	7
540	Medication non-adherence: the hidden problem in clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 923-924	4.6	0
539	Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 323-332	4.6	14
538	Motivational interviewing-based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well study. <i>British Journal of Dermatology</i> , 2017 , 176, 677-686	4	22
537	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 928-938	4	119
536	Lysyl oxidase activity in human skin is increased by chronic ultraviolet radiation exposure and smoking. <i>British Journal of Dermatology</i> , 2017 , 176, 1376-1378	4	8
535	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017 , 176, 890-901	4	79
534	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 119-126	4.6	68
533	Novel approaches to characterize age-related remodelling of the dermal-epidermal junction in 2D, 3D and in vivo. <i>Skin Research and Technology</i> , 2017 , 23, 131-148	1.9	21
532	Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. <i>British Journal of Dermatology</i> , 2017 , 176, 650-658	4	115
531	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017 , 176, 1297-1307	4	37
530	Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 667-676	4	31
529	A visual literacy course for dermatology trainees. <i>British Journal of Dermatology</i> , 2017 , 177, 310-311	4	6
528	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017 , 26, 4301-4313 ^{5,6}	5.6	25
527	The 2016 International League of Dermatological Societies' revised glossary for the description of cutaneous lesions. <i>British Journal of Dermatology</i> , 2016 , 174, 1351-8	4	25
526	Interleukin-17 and interleukin-23 regulate Langerhans cell migration. <i>British Journal of Dermatology</i> , 2016 , 175, 622-4	4	3

525	Primary care-based screening for cardiovascular risk factors in patients with psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 348-56	4	19
524	Paradoxical exacerbation of chronic plaque psoriasis by sorafenib. <i>Clinical and Experimental Dermatology</i> , 2016 , 41, 407-9	1.8	5
523	Communicating Cardiovascular Disease Risk to People with Psoriasis: What Techniques do Practitioners Use?. <i>International Journal of Behavioral Medicine</i> , 2016 , 23, 168-78	2.6	5
522	A novel mutation in IL36RN underpins childhood pustular dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 302-5	4.6	9
521	P16INK4a Positive Cells in Human Skin Are Indicative of Local Elastic Fiber Morphology, Facial Wrinkling, and Perceived Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016 , 71, 1022-8	6.4	33
520	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016 , 308, 201-5	3.3	29
519	The impact of intrinsic ageing on the protein composition of the dermal-epidermal junction. <i>Mechanisms of Ageing and Development</i> , 2016 , 156, 14-6	5.6	45
518	'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study. <i>Health Expectations</i> , 2016 , 19, 1121-37	3.7	18
517	Ixekizumab for psoriasis--Authors' reply. <i>Lancet, The</i> , 2016 , 387, 226-7	4.0	3
516	Novel systemic therapies for the treatment of psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 79-92	4	14
515	Measurement, Classification and Evaluation of Sleep Disturbance in Psoriasis: A Systematic Review. <i>PLoS ONE</i> , 2016 , 11, e0157843	3.7	30
514	Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and Structure. <i>Acta Dermato-Venereologica</i> , 2016 , 96, 641-4	2.2	13
513	Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. <i>British Journal of Dermatology</i> , 2016 , 174, 985-95	4	51
512	Brain inflammation and psoriasis: a [¹⁸ C]-(R)-PK11195 positron emission tomography study. <i>British Journal of Dermatology</i> , 2016 , 175, 1082-1084	4	11
511	THU0187 Safety of Tofacitinib, An Oral Janus Kinase Inhibitor: Integrated Data Analysis from The Global Chronic Plaque Psoriasis Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 253.1-253	2.4	
510	Age-Associated Skin Conditions and Diseases: Current Perspectives and Future Options. <i>Gerontologist, The</i> , 2016 , 56 Suppl 2, S230-42	5	87
509	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 83-98.e4	4.5	212
508	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1584-1591	4.3	49

507	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. <i>British Journal of Dermatology</i> , 2016 , 175, 1038-1044	4	28
506	The role of personal models in clinical management: Exploring health care providers' beliefs about psoriasis. <i>British Journal of Health Psychology</i> , 2016 , 21, 114-34	8.3	7
505	The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 86-91	4.6	12
504	Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise. <i>British Journal of Dermatology</i> , 2016 , 174, 212-5	4	6
503	Pilot study assessing pathophysiology and healing of digital ulcers in patients with systemic sclerosis using laser Doppler imaging and thermography. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 100-105	2.2	8
502	Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. <i>British Journal of Dermatology</i> , 2015 , 172, 230-8	4	13
501	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 329-34	2.8	8
500	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015 , 172, 1395-406	4	106
499	A Genome-Wide Association Study Identifies the Skin Color Genes IRF4, MC1R, ASIP, and BNC2 Influencing Facial Pigmented Spots. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1735-1742	4.3	80
498	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 37-49	4.5	360
497	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 103-12	2.8	28
496	Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2964-2970	4.3	58
495	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. <i>Lancet, The</i> , 2015 , 386, 541-51	4.0	576
494	A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 291-6	2.8	3
493	Disentangling the effects of circulating IGF-1, glucose, and cortisol on features of perceived age. <i>Age</i> , 2015 , 37, 9771		4
492	Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2189-2197	4.3	96
491	Acne conglobata and adalimumab: use of tumour necrosis factor-antagonists in treatment-resistant acne conglobata, and review of the literature. <i>Clinical and Experimental Dermatology</i> , 2015 , 40, 383-6	1.8	23
490	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S48	4.0	12

489	The acceptability and usefulness of mindfulness-based cognitive therapy for people living with psoriasis: a qualitative study. <i>British Journal of Dermatology</i> , 2015 , 172, 823-5	4	10
488	Lifestyle and youthful looks. <i>British Journal of Dermatology</i> , 2015 , 172, 1338-45	4	19
487	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2011-9	9.5	69
486	Do English healthcare settings use 'Choice Architecture' principles in promoting healthy lifestyles for people with psoriasis? An observational study. <i>BMC Health Services Research</i> , 2015 , 15, 215	2.9	4
485	Psoriasis treatment and management - a systematic review of full economic evaluations. <i>British Journal of Dermatology</i> , 2015 , 172, 574-83	4	10
484	Psoriasis: the future. <i>Dermatologic Clinics</i> , 2015 , 33, 161-6	4.2	14
483	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 224-231	4.6	25
482	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015 , 172, 933-9	4	12
481	Markers of health and disease and pigmented spots in a middle-aged population. <i>British Journal of Dermatology</i> , 2015 , 173, 1550-2	4	7
480	A fresh look at T cells in psoriasis. <i>British Journal of Dermatology</i> , 2015 , 173, 891-2	4	
479	Patient-reported outcome measures in psoriasis: the good, the bad and the missing!. <i>British Journal of Dermatology</i> , 2015 , 172, 1210-21	4	34
478	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015 , 173, 510-8	4	67
477	Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. <i>British Journal of Dermatology</i> , 2015 , 173, 1271-3	4	8
476	A pilot study examining mindfulness-based cognitive therapy in psoriasis. <i>Psychology, Health and Medicine</i> , 2015 , 20, 121-7	2.1	52
475	The role of beliefs: lessons from a pilot study on illness perception, psychological distress and quality of life in patients with primary cicatricial alopecia. <i>British Journal of Dermatology</i> , 2015 , 172, 130-7		51
474	A potential role for endogenous proteins as sacrificial sunscreens and antioxidants in human tissues. <i>Redox Biology</i> , 2015 , 5, 101-113	11.3	37
473	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2632-2640	4.3	262
472	Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. <i>Molecular BioSystems</i> , 2015 , 11, 2198-209		14

471	Over-the-counter anti-ageing topical agents and their ability to protect and repair photoaged skin. <i>Maturitas</i> , 2015 , 80, 265-72	5	14
470	Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 468-73	4.6	10
469	Damage to skin extracellular matrix induced by UV exposure. <i>Antioxidants and Redox Signaling</i> , 2014 , 21, 1063-77	8.4	81
468	Geographical ancestry is a key determinant of epidermal morphology and dermal composition. <i>British Journal of Dermatology</i> , 2014 , 171, 274-82	4	23
467	Naevus sebaceus: a mosaic RASopathy. <i>Clinical and Experimental Dermatology</i> , 2014 , 39, 1-6	1.8	36
466	Epicutaneous exposure to proteins and skin immune function. <i>European Journal of Dermatology</i> , 2014 , 24, 10-4	0.8	12
465	A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. <i>Rheumatology</i> , 2014 , 53, 1422-30	3.9	20
464	Skin health in older age. <i>Maturitas</i> , 2014 , 79, 256-64	5	36
463	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014 , 14, 47-53	1.9	7
462	In vitro and in vivo studies with tetra-hydro-jasmonic acid (LR2412) reveal its potential to correct signs of skin ageing. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 415-23	4.6	18
461	Secukinumab in plaque psoriasis--results of two phase 3 trials. <i>New England Journal of Medicine</i> , 2014 , 371, 326-38	59.2	1319
460	AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. <i>American Journal of Human Genetics</i> , 2014 , 94, 790-7	11	105
459	Scanning acoustic microscopy of biological cryosections: the effect of local thickness on apparent acoustic wave speed. <i>Materials Research Society Symposia Proceedings</i> , 2014 , 1621, 143-148		
458	'In someone's clinic but not in mine'--clinicians' views of supporting lifestyle behaviour change in patients with psoriasis: a qualitative interview study. <i>British Journal of Dermatology</i> , 2014 , 171, 1116-22	4	22
457	Treatment-related restoration of Langerhans cell migration in psoriasis. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 268-271	4.3	16
456	Responsiveness to change and interpretability of the simplified psoriasis index. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 351-358	4.3	19
455	Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1459-1462	4.3	19
454	Guttate psoriasis is associated with an intermediate phenotype of impaired Langerhans cell migration. <i>British Journal of Dermatology</i> , 2014 , 171, 409-11	4	8

453	Topical photodynamic therapy following excisional wounding of human skin increases production of transforming growth factor- β and matrix metalloproteinases 1 and 9, with associated improvement in dermal matrix organization. <i>British Journal of Dermatology</i> , 2014 , 171, 55-62	4	23
452	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2014 , 170, 206-9	4	7
451	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. <i>British Journal of Dermatology</i> , 2014 , 171, 485-91	4	28
450	Providing lifestyle behaviour change support for patients with psoriasis: an assessment of the existing training competencies across medical and nursing health professionals. <i>British Journal of Dermatology</i> , 2014 , 171, 602-8	4	12
449	Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1750-2	2.4	21
448	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014 , 53, 213-22	3.9	137
447	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 61-2	2.8	1
446	Expression of microRNA-184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013 , 228, 2314-23	7	29
445	Does psychosocial stress play a role in the exacerbation of psoriasis?. <i>British Journal of Dermatology</i> , 2013 , 169, 965-74	4	51
444	Adherence to medication in patients with psoriasis: a systematic literature review. <i>British Journal of Dermatology</i> , 2013 , 168, 20-31	4	109
443	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. <i>British Journal of Dermatology</i> , 2013 , 168, 864-6	4	10
442	Cutaneous <i>Mycobacterium haemophilum</i> infection in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2013 , 168, 446-7	4	5
441	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013 , 168, 374-80	4	12
440	Recognition of need in health care consultations: a qualitative study of people with psoriasis. <i>British Journal of Dermatology</i> , 2013 , 168, 354-61	4	49
439	Challenges and approaches for the development of safer immunomodulatory biologics. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 306-24	64.1	106
438	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. <i>British Journal of Dermatology</i> , 2013 , 168, 844-54	4	284
437	Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1366-9	4.3	109
436	A novel, web-based, psychological intervention for people with psoriasis: the electronic Targeted Intervention for Psoriasis (eTIPs) study. <i>British Journal of Dermatology</i> , 2013 , 169, 329-36	4	40

435	Can stress reduction interventions improve psoriasis? A review. <i>Psychology, Health and Medicine</i> , 2013 , 18, 501-14	2.1	17
434	Cross-linking of structural proteins in ageing skin: an in situ assay for the detection of amine oxidase activity. <i>Biogerontology</i> , 2013 , 14, 89-97	4.5	23
433	A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. <i>Scandinavian Journal of Rheumatology</i> , 2013 , 42, 483-6	1.9	41
432	Global epidemiology of psoriasis: a systematic review of incidence and prevalence. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 377-85	4.3	1392
431	The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1956-62	4.3	43
430	Dr. Murray, et al reply. <i>Journal of Rheumatology</i> , 2013 , 40, 206	4.1	1
429	Biologic therapies in dermatology. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013 , 74, 12-7	0.8	
428	Facial appearance reflects human familial longevity and cardiovascular disease risk in healthy individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2013 , 68, 145-52	6.4	28
427	'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. <i>BMC Family Practice</i> , 2013 , 14, 158	2.6	42
426	Alemtuzumab and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2013 , 169, 184-6	4	2
425	Dopamine is a novel, direct inducer of catagen in human scalp hair follicles in vitro. <i>British Journal of Dermatology</i> , 2013 , 168, 520-5	4	14
424	Serum insulin-like growth factor 1 and facial ageing: high levels associate with reduced skin wrinkling in a cross-sectional study. <i>British Journal of Dermatology</i> , 2013 , 168, 533-8	4	19
423	Lichen planopilaris is characterized by immune privilege collapse of the hair follicle's epithelial stem cell niche. <i>Journal of Pathology</i> , 2013 , 231, 236-47	9.4	154
422	Tumour necrosis factor alpha, interferon gamma and substance P are novel modulators of extrapituitary prolactin expression in human skin. <i>PLoS ONE</i> , 2013 , 8, e60819	3.7	17
421	A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 12-7	2.2	8
420	A temporal analysis of the central neural processing of itch. <i>British Journal of Dermatology</i> , 2012 , 166, 994-1001	4	25
419	Twenty top tips to triumph in dermatology. <i>British Journal of Dermatology</i> , 2012 , 167, 445-6	4	
418	Primary cicatricial alopecias: a U.K. survey. <i>British Journal of Dermatology</i> , 2012 , 167, 694-7	4	16

417	Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. <i>British Journal of Dermatology</i> , 2012 , 167, 563-9	4	16
416	Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26 Suppl 5, 2-8	4.6	5
415	In search of oral psoriasis. <i>Archives of Dermatological Research</i> , 2012 , 304, 1-5	3.3	26
414	Exploring the role of prolactin in psoriasis. <i>Archives of Dermatological Research</i> , 2012 , 304, 115-8	3.3	15
413	Investigational VEGF antagonists for psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 33-43	5.9	27
412	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2012 , 66, 731-41	4.5	82
411	Chemical consequences of cutaneous photoageing. <i>Chemistry Central Journal</i> , 2012 , 6, 34		20
410	Commentary: Biologics for psoriasis: steps to heaven 17. <i>British Journal of Dermatology</i> , 2012 , 167, 715-64		1
409	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012 , 44, 1341-8	36.3	681
408	So you want to be a clinical academic. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012 , 73, C23-5	0.8	1
407	Differential expression of elastic fibre components in intrinsically aged skin. <i>Biogerontology</i> , 2012 , 13, 37-48	4.5	26
406	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012 , 166, 189-95	4	30
405	Lichen planopilaris following hair transplantation and face-lift surgery. <i>British Journal of Dermatology</i> , 2012 , 166, 666-370	4	50
404	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012 , 166, 474-82	4	48
403	The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012 , 166, 545-54	4	81
402	No impairment of monocyte-derived Langerhans cell phenotype or function in early-onset psoriasis. <i>Clinical and Experimental Dermatology</i> , 2012 , 37, 40-7	1.8	7
401	Utilizing the hair follicle to dissect the regulation and autocrine/paracrine activities of prolactin in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012 , 302, E1311-2	6	8
400	Noninvasive measurement of skin autofluorescence is increased in patients with systemic sclerosis: an indicator of increased advanced glycation endproducts?. <i>Journal of Rheumatology</i> , 2012 , 39, 1654-8	4.1	14

399	An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. <i>Journal of Drugs in Dermatology</i> , 2012 , 11, 300-12	2.2	45
398	Improving clinical trial design in psoriasis: Perspectives from the global dermatology community. <i>Journal of Dermatological Treatment</i> , 2011 , 22, 187-93	2.8	4
397	Specific Therapeutic Agents 2011 , 205-317		
396	Evaluation of educational methods in dermatology and confidence levels: a national survey of UK medical students. <i>International Journal of Dermatology</i> , 2011 , 50, 198-202	1.7	24
395	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , 2011 , 164, 660-4	4	20
394	The effect of ageing on phenotype and function of monocyte-derived Langerhans cells. <i>British Journal of Dermatology</i> , 2011 , 165, 184-8	4	19
393	What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. <i>Clinical and Experimental Dermatology</i> , 2011 , 36, 585-9; quiz 588-9	1.8	7
392	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. <i>British Journal of Dermatology</i> , 2011 , 164, 862-72	4	93
391	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011 , 12, 815-26	2.6	59
390	Definition of treatment goals for moderate to severe psoriasis: a European consensus. <i>Archives of Dermatological Research</i> , 2011 , 303, 1-10	3.3	527
389	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1016-9	2.4	60
388	The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 548-54	4.6	103
387	Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1371-7	4.6	31
386	Comparing biological therapies in psoriasis: implications for clinical practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24 Suppl 6, 10-4	4.6	13
385	Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. <i>British Journal of Dermatology</i> , 2010 , 162, 1127-31	4	25
384	Management of psoriasis in pregnancy: time to deliver?. <i>British Journal of Dermatology</i> , 2010 , 163, 235	4	5
383	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2010 , 163, 859-62	4	19
382	What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 688-91; quiz 692	1.8	5

381	Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle?. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 886-91	4.3	32
380	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010 , 42, 985-90	36.3	773
379	A tooth for an eye: cicatricial pemphigoid and the osteo-odonto-keratoprosthesis. <i>Archives of Dermatology</i> , 2010 , 146, 1188-9		2
378	Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. <i>Journal of Investigative Dermatology</i> , 2010 , 130, 1940-2	4.3	21
377	Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. <i>Dermatology</i> , 2010 , 221, 172-8	4.4	42
376	Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. <i>New England Journal of Medicine</i> , 2010 , 362, 118-28	59.2	675
375	Tissue section AFM: In situ ultrastructural imaging of native biomolecules. <i>Matrix Biology</i> , 2010 , 29, 254-60	6.4	82
374	The future of biological therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010 , 29, 63-6	1.4	18
373	Does collapse of immune privilege in the hair-follicle bulge play a role in the pathogenesis of primary cicatricial alopecia?. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 637-44	1.8	28
372	Evidence for the presence of bacteria in the blood of psoriasis patients. <i>Archives of Dermatological Research</i> , 2010 , 302, 495-8	3.3	38
371	Low-dose ultraviolet radiation selectively degrades chromophore-rich extracellular matrix components. <i>Journal of Pathology</i> , 2010 , 222, 32-40	9.4	50
370	A new wrinkle on old skin: the role of elastic fibres in skin ageing. <i>International Journal of Cosmetic Science</i> , 2010 , 32, 330-9	2.7	109
369	2010 ,		103
368	Why some women look young for their age. <i>PLoS ONE</i> , 2009 , 4, e8021	3.7	144
367	Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1103-11		93
366	Liver X receptor β maintenance of epidermal expression in intrinsic and extrinsic skin aging. <i>Age</i> , 2009 , 31, 365-72		2
365	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2009 , 160, 162-9	4	43
364	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009 , 160, 438-41	4	55

363	Pilot study of dual-wavelength (532 and 633 nm) laser Doppler imaging and infrared thermography of morphea. <i>British Journal of Dermatology</i> , 2009 , 160, 864-7	4	24
362	Care of patients with psoriasis: an audit of U.K. services in secondary care. <i>British Journal of Dermatology</i> , 2009 , 160, 557-64	4	21
361	How not to get scar(r)ed: pointers to the correct diagnosis in patients with suspected primary cicatricial alopecia. <i>British Journal of Dermatology</i> , 2009 , 160, 482-501	4	74
360	Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. <i>British Journal of Dermatology</i> , 2009 , 161 Suppl 2, 1-30	4	5
359	Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]. <i>British Journal of Dermatology</i> , 2009 , 161, 419-26	4	53
358	Evidence for an 'anti-ageing' product may not be so clear as it appears: reply from authors. <i>British Journal of Dermatology</i> , 2009 , 161, 1208-1209	4	1
357	British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009 , 161, 987-1019	4	356
356	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 415-6	1.8	15
355	An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 618-20	1.8	2
354	Defining cancer risk in dermatomyositis. Part I. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 451-5	1.8	39
353	Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 561-5	1.8	29
352	What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 664-7	1.8	7
351	Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. <i>Genes and Immunity</i> , 2009 , 10, 654-8	4.4	43
350	Severely photosensitive psoriasis: a phenotypically defined patient subset. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2861-7	4.3	15
349	Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging. <i>Journal of Cosmetic Dermatology</i> , 2009 , 8, 228-33	2.5	20
348	Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23, 1374-82	4.6	67
347	European S3-guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009 , 23 Suppl 2, 1-70	4.6	586
346	Future therapeutic directions for the treatment of psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2009 , 100 Suppl 2, 28-31	0.5	1

345	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009 , 1, 72	14.4	12
344	Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 2613-9	4.3	32
343	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009 , 4, 15-21		1
342	No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 2904-5	4.3	5
341	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1925-9	4.3	88
340	Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 2219-24	4.3	29
339	Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1325-7	4.3	66
338	The effects of acute social stress on epidermal Langerhans' cell frequency and expression of cutaneous neuropeptides. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1273-9	4.3	37
337	Psoriasis: consensus on topical therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 859-70	4.6	27
336	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. <i>British Journal of Dermatology</i> , 2008 , 158, 962-8	4	33
335	Management of primary cicatricial alopecias: options for treatment. <i>British Journal of Dermatology</i> , 2008 , 159, 1-22	4	80
334	Making a 'point' about the safe disposal of sharps in patients on biological therapies. <i>British Journal of Dermatology</i> , 2008 , 159, 491-2	4	4
333	A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. <i>British Journal of Dermatology</i> , 2008 , 159, 942-51	4	54
332	Methotrexate for psoriasis in the era of biological therapy. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 551-4	1.8	48
331	Topical treatments for scalp psoriasis. <i>Drugs</i> , 2008 , 68, 2293-302	12.1	9
330	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 224-31	4.5	131
329	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. <i>Clinics in Dermatology</i> , 2008 , 26, 438-47	3	59
328	Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1237-54	2.5	40

327	Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008 , 17, 1938-45	5.6	151
326	Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. <i>Expert Review of Dermatology</i> , 2008 , 3, 657-665		34
325	Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. <i>Dermatology</i> , 2008 , 217, 268-75	4.4	32
324	A review of tazarotene in the treatment of photodamaged skin. <i>Clinical Interventions in Aging</i> , 2008 , 3, 71-6	4	13
323	The Greater Patient concept. <i>British Journal of Dermatology</i> , 2008 , 158, 176-8	4	7
322	Alcohol consumption and psychological distress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2008 , 158, 138-40	4	77
321	Inpatient management of psoriasis: a multicentre service review to establish national admission standards. <i>British Journal of Dermatology</i> , 2008 , 158, 266-72	4	12
320	Repair of photoaged dermal matrix by topical application of a cosmetic 'antiageing' product. <i>British Journal of Dermatology</i> , 2008 , 158, 472-7	4	51
319	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. <i>Archives of Dermatological Research</i> , 2008 , 300, 537-44	3.3	44
318	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3705-9		108
317	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. <i>Experimental Dermatology</i> , 2008 , 17, 228-40	4	25
316	Viewpoint 2. <i>Experimental Dermatology</i> , 2008 , 17, 230-231	4	
315	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 672-6	2.4	107
314	Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. <i>Journal of Medical Genetics</i> , 2008 , 45, 114-6	5.8	104
313	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 677-82	2.4	76
312	How best to halt and/or revert UV-induced skin ageing: strategies, facts and fiction. <i>Experimental Dermatology</i> , 2008 , 17, 228-240	4	8
311	The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3151-9	15.9	118
310	Illness perception in individuals with atopic dermatitis. <i>Psychology, Health and Medicine</i> , 2007 , 12, 433-442	4.1	40

309	Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg. <i>Trials</i> , 2007 , 8, 3	2.8	7
308	Altered claudin expression is a feature of chronic plaque psoriasis. <i>Journal of Pathology</i> , 2007 , 212, 450-8	3.4	62
307	Increased blood levels of IgG reactive with secreted <i>Streptococcus pyogenes</i> proteins in chronic plaque psoriasis. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1337-42	4.3	24
306	Filaggrin null alleles are not associated with psoriasis. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1878-82	4.3	36
305	Salicyloyl-phytosphingosine: a novel agent for the repair of photoaged skin. <i>International Journal of Cosmetic Science</i> , 2007 , 29, 319-29	2.7	19
304	A classification of psoriasis vulgaris according to phenotype. <i>British Journal of Dermatology</i> , 2007 , 156, 258-62	4	190
303	Systemic ciclosporin and tacrolimus in dermatology. <i>Dermatologic Therapy</i> , 2007 , 20, 239-50	2.2	59
302	Guidelines for Logbook for registration of training activities in dermatology and venereology: report from the Board of Dermatology and Venereology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007 , 21, 850-1	4.6	
301	An Examination of the Psychometric Properties and Factor Structure of the Feelings of Stigmatization Questionnaire. <i>Journal of Clinical Psychology in Medical Settings</i> , 2007 , 14, 248-257	2	1
300	Nuclear hormone receptors in human skin. <i>Hormone and Metabolic Research</i> , 2007 , 39, 96-105	3.1	50
299	Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. <i>Archives of Dermatology</i> , 2007 , 143, 1175-9		52
298	Pathogenesis and clinical features of psoriasis. <i>Lancet, The</i> , 2007 , 370, 263-271	40	1221
297	Current and future management of psoriasis. <i>Lancet, The</i> , 2007 , 370, 272-284	40	235
296	Anti-aging Effects of Retinoids and Mechanisms of Action. <i>Basic and Clinical Dermatology</i> , 2007 , 77-102		
295	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. <i>European Journal of Dermatology</i> , 2007 , 17, 381-6	0.8	22
294	Biological therapy for psoriasis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2006 , 67, 184-7	0.8	1
293	Infliximab for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2006 , 6, 797-805	5.4	32
292	A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2006 , 17, 90-5	2.8	40

291	Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. <i>Gut</i> , 2006 , 55, 505-9	19.2	380
290	Pyoderma gangrenosum masquerading as dermatitis artefacta. <i>Archives of Dermatology</i> , 2006 , 142, 1509-10		12
289	Impaired Langerhans cell migration in psoriasis. <i>Journal of Experimental Medicine</i> , 2006 , 203, 953-60	16.6	91
288	Photoageing: the darker side of the sun. <i>Photochemical and Photobiological Sciences</i> , 2006 , 5, 160-4	4.2	34
287	A European perspective on the challenges of managing psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S81-4	4.5	19
286	Interventions for chronic palmoplantar pustulosis. <i>The Cochrane Library</i> , 2006 , CD001433	5.2	35
285	Adherence to treatment in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 370-9	4.6	109
284	The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 921-5	4.6	19
283	The use of retinoids in the treatment of photoaging. <i>Dermatologic Therapy</i> , 2006 , 19, 297-305	2.2	38
282	The CX3CL1-CX3CR1 system and psoriasis. <i>Experimental Dermatology</i> , 2006 , 15, 900-3	4	21
281	Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. <i>British Journal of Dermatology</i> , 2006 , 154, 345-52	4	62
280	Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2006 , 154, 977-8	4	136
279	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006 , 154, 1161-8	4	92
278	Update on the use of ciclosporin in immune-mediated dermatoses. <i>British Journal of Dermatology</i> , 2006 , 155 Suppl 2, 1-16	4	45
277	The impact of psoriasis guidelines on appropriateness of referral from primary to secondary care: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2006 , 155, 393-400	4	20
276	Striae gravidarum in primiparae. <i>British Journal of Dermatology</i> , 2006 , 155, 965-9	4	91
275	The role of neuropeptides in psoriasis. <i>British Journal of Dermatology</i> , 2006 , 155, 876-82	4	86
274	Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. <i>British Journal of Dermatology</i> , 2006 , 155, 1236-41	4	30

273	Proteomic analysis of suction blister fluid isolated from human skin. <i>Clinical and Experimental Dermatology</i> , 2006 , 31, 445-8	1.8	28
272	Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 453-9	4.3	84
271	Anti-TNF drugs in psoriasis and IBD - Where are we going?. <i>Future Prescriber</i> , 2006 , 7, 14-20		
270	Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. <i>Clinical and Experimental Rheumatology</i> , 2006 , 24, S72-8	2.2	28
269	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. <i>Lancet, The</i> , 2005 , 366, 1367-74	4.0	850
268	Psychologic factors in psoriasis: consequences, mechanisms, and interventions. <i>Dermatologic Clinics</i> , 2005 , 23, 681-94	4.2	176
267	Efalizumab. <i>American Journal of Clinical Dermatology</i> , 2005 , 6, 119-120	7.1	1
266	Optimal management of severe plaque form of psoriasis. <i>American Journal of Clinical Dermatology</i> , 2005 , 6, 283-94	7.1	12
265	Adversarial growth in patients undergoing treatment for psoriasis: A prospective study of the ability of patients to construe benefits from negative events. <i>Psychology, Health and Medicine</i> , 2005 , 10, 44-56	2.1	20
264	Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. <i>Journal of the American Academy of Dermatology</i> , 2005 , 52, 468-73	4.5	64
263	Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. <i>Journal of Psychosomatic Research</i> , 2005 , 58, 89-96	4.1	59
262	Cytokines and Langerhans cell mobilisation in mouse and man. <i>Cytokine</i> , 2005 , 32, 67-70	4	95
261	Psoriasis: epidemiology, clinical features, and quality of life. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii18-23; discussion ii24-5	2.4	395
260	Modern management of psoriasis. <i>Clinical Medicine</i> , 2005 , 5, 564-8	1.9	0
259	Pathogenic aspects of cutaneous photoaging. <i>Journal of Cosmetic Dermatology</i> , 2005 , 4, 230-6	2.5	34
258	Gene expression profiles in psoriasis: analysis of impact of body site location and clinical severity. <i>British Journal of Dermatology</i> , 2005 , 152, 489-504	4	32
257	Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. <i>British Journal of Dermatology</i> , 2005 , 152, 1182-6	4	15
256	Ciclosporin in psoriasis consensus statement. <i>British Journal of Dermatology</i> , 2005 , 152, 811; author reply 811	4	

255	Ciclosporin in psoriasis consensus statement: reply from authors. <i>British Journal of Dermatology</i> , 2005 , 152, 811-811	4	
254	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. <i>British Journal of Dermatology</i> , 2005 , 152, 597-615	4	146
253	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005 , 152, 1214-27	4	44
252	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. <i>British Journal of Dermatology</i> , 2005 , 152, 1304-12	4	586
251	Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases. <i>British Journal of Dermatology</i> , 2005 , 153, 549-51	4	40
250	Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. <i>British Journal of Dermatology</i> , 2005 , 153, 1114-20	4	83
249	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. <i>British Journal of Dermatology</i> , 2005 , 153, 869-73	4	21
248	British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. <i>British Journal of Dermatology</i> , 2005 , 153, 486-97	4	199
247	Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. <i>British Journal of Dermatology</i> , 2005 , 153, 1192-9	4	111
246	The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 103-6	4.3	68
245	Controversies in Experimental Dermatology. <i>Experimental Dermatology</i> , 2005 , 14, 398-399	4	
244	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1694-9		239
243	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3596-602		60
242	Worry and Pathological Worry in Patients with Psoriasis: Cross Sectional and Longitudinal Analyses of the Penn State Worry Questionnaire (PSWQ) in Four Samples of Patients. <i>Journal of Clinical Psychology in Medical Settings</i> , 2005 , 12, 143-152	2	8
241	Guideline for anti-TNF-alpha therapy in psoriatic arthritis. <i>Rheumatology</i> , 2005 , 44, 390-7	3.9	105
240	Treatment of photoaged skin with a cream containing 0.05% isotretinoin and sunscreens. <i>Journal of Dermatological Treatment</i> , 2005 , 16, 79-86	2.8	15
239	Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. <i>Dermatology</i> , 2005 , 211, 256-63	4.4	18
238	Interventions for photodamaged skin. <i>Cochrane Database of Systematic Reviews</i> , 2005 , CD001782		26

237	T-cell-targeted biologicals for psoriasis. <i>Inflammation and Allergy: Drug Targets</i> , 2004 , 3, 157-61		6
236	Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 892-7	5.6	150
235	Exogenous interleukin-1beta restores impaired Langerhans cell migration in aged skin. <i>British Journal of Dermatology</i> , 2004 , 150, 1217-8	4	24
234	Streptococcal infection may make psoriasis worse but do antibiotics help?. <i>British Journal of Dermatology</i> , 2004 , 151, 244-5; author reply 245	4	1
233	CARD15/NOD2 single nucleotide polymorphisms do not confer susceptibility to type I psoriasis. <i>British Journal of Dermatology</i> , 2004 , 151, 675-8	4	21
232	Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. <i>British Journal of Dermatology</i> , 2004 , 151, 1227-33	4	98
231	Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. <i>British Journal of Dermatology</i> , 2004 , 151, 1219-26	4	54
230	Competency assessment of dermatology trainees in the UK. <i>Clinical and Experimental Dermatology</i> , 2004 , 29, 571-5	1.8	6
229	Ciclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , 2004 , 150 Suppl 67, 11-23	4	115
228	Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation. <i>Experimental Dermatology</i> , 2004 , 13, 452-60	4	24
227	Divergent beliefs about psoriasis are associated with increased psychological distress. <i>Journal of Investigative Dermatology</i> , 2004 , 123, 49-56	4.3	41
226	Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. <i>Journal of Investigative Dermatology</i> , 2004 , 123, 484-7	4.3	61
225	Retinoic acid receptor alpha expression and cutaneous ageing. <i>Mechanisms of Ageing and Development</i> , 2004 , 125, 465-73	5.6	19
224	Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. <i>British Journal of Clinical Psychology</i> , 2004 , 43, 65-82	3.6	76
223	Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. <i>Journal of Investigative Dermatology</i> , 2004 , 122, 209-15	4.3	110
222	Therapeutic potential of macrolide immunosuppressants in dermatology. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 125-37	5.9	1
221	Psoriasis: future research needs and goals for the twenty-first century. <i>Dermatologic Clinics</i> , 2004 , 22, 493-9, x	4.2	10
220	Associations between UVR exposure and basal cell carcinoma site and histology. <i>Cancer Letters</i> , 2004 , 216, 191-7	9.9	16

219	The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. <i>Journal of Psychosomatic Research</i> , 2004 , 57, 195-200	4.1	113
218	An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. <i>Archives of Dermatology</i> , 2003 , 139, 719-27		271
217	Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. <i>Journal of Dermatological Treatment</i> , 2003 , 14, 14-21	2.8	13
216	Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. <i>Journal of Behavioral Medicine</i> , 2003 , 26, 211-24	3.6	32
215	Epidermal Langerhans cell migration and sensitisation to chemical allergens. <i>Apmis</i> , 2003 , 111, 797-804	3.4	63
214	A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis. <i>Experimental Dermatology</i> , 2003 , 12, 506-9	4	23
213	Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. <i>Journal of Investigative Dermatology</i> , 2003 , 120, 627-32	4.3	145
212	Resetting the research agenda for psoriasis. <i>Journal of Investigative Dermatology</i> , 2003 , 120, ix-x	4.3	8
211	The immunological basis of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003 , 17 Suppl 2, 1-5	4.6	37
210	Circulating natural killer cells in psoriasis. <i>British Journal of Dermatology</i> , 2003 , 149, 160-4	4	70
209	Stigmatization and psoriasis. <i>British Journal of Dermatology</i> , 2003 , 149, 209-11	4	35
208	Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. <i>British Journal of Dermatology</i> , 2003 , 149, 323-31	4	106
207	Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings. <i>Clinical and Experimental Dermatology</i> , 2003 , 28, 64-9	1.8	27
206	Keloidal scleroderma. <i>Clinical and Experimental Dermatology</i> , 2003 , 28, 171-3	1.8	10
205	Papuloerythroderma of Ofuji associated with acute myeloid leukaemia. <i>Clinical and Experimental Dermatology</i> , 2003 , 28, 277-9	1.8	9
204	IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin. <i>Clinical and Experimental Immunology</i> , 2003 , 132, 352-9	6.2	88
203	Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. <i>Journal of the American Academy of Dermatology</i> , 2003 , 49, 83-90	4.5	83
202	Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. <i>Archives of Dermatology</i> , 2003 , 139, 752-6		147

201 Photoageing **2003**, 399-401200 Natural killer and natural killer-T cells in psoriasis. *Archives of Dermatological Research*, **2002**, 294, 363-9 3,3 94199 Tumour necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. *British Journal of Dermatology*, **2002**, 146, 32-40 4 95198 Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. *British Journal of Dermatology*, **2002**, 146, 414-22 4 49197 A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. *British Journal of Dermatology*, **2002**, 146, 458-65 4 176196 Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. *British Journal of Dermatology*, **2002**, 146, 824-31 4 110195 Novel immune-based therapies for psoriasis. *British Journal of Dermatology*, **2002**, 146, 546-51 4 33194 Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. *British Journal of Dermatology*, **2002**, 147, 299-307 4 39193 Enumeration of the frequency of Langerhans cells in epidermis. *British Journal of Dermatology*, **2002**, 147, 1277-8; author reply 1278 4192 Enumeration of the frequency of Langerhans cells in epidermis: reply from authors. *British Journal of Dermatology*, **2002**, 147, 1278-1278 4191 Recent advances in cutaneous angiogenesis. *British Journal of Dermatology*, **2002**, 147, 418-25 4 49190 Downregulation and altered spatial pattern of caveolin-1 in chronic plaque psoriasis. *British Journal of Dermatology*, **2002**, 147, 701-9 4 18189 Fibulin-2 and its association with fibrillin-rich microfibrils in the papillary dermis of photoaged skin. *British Journal of Dermatology*, **2002**, 146, 712 4 1188 Danger signals and skin sensitization. *British Journal of Dermatology*, **2002**, 147, 613-4 4 23187 Patients' strategies for coping with psoriasis. *Clinical and Experimental Dermatology*, **2002**, 27, 177-84 1.8 46186 Cytokine blocking agents in dermatology. *Clinical and Experimental Dermatology*, **2002**, 27, 585-90 1.8 40185 Wirksamkeit und Sicherheit von Tacalcitol-Salbe in der Langzeitanwendung bei chronischer Plaque Psoriasis. *Zeitschrift für Hautkrankheiten*, **2002**, 77, 424-432 2184 Die Zytokin-Blocker in der Dermatologie. *Zeitschrift für Hautkrankheiten*, **2002**, 77, 663-668

183	Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. <i>British Journal of Clinical Psychology</i> , 2002 , 41, 157-74	3.6	138
182	Gougerot-Carteaud still an enigma after all these years. <i>Journal of Dermatological Treatment</i> , 2002 , 13, 1	2.8	10
181	Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. <i>Biochemistry and Cell Biology</i> , 2002 , 80, 103-7	3.6	42
180	Immunotherapy for psoriasis: from serendipity to selectivity. <i>Lancet, The</i> , 2002 , 359, 279-80	40	20
179	An investigation of the effect of prolonged glove wearing on the hand skin health of dental healthcare workers. <i>Journal of Dentistry</i> , 2002 , 30, 233-41	4.8	8
178	Topical retinoids for the ageing face 2002 , 13-23		
177	The macrolide immunosuppressants in dermatology: mechanisms of action. <i>European Journal of Dermatology</i> , 2002 , 12, 618-22	0.8	55
176	Epidermal and dermal abnormalities. <i>European Journal of Dermatology</i> , 2002 , 12, XIX-XX	0.8	1
175	Distribution and expression of type VI collagen in photoaged skin. <i>British Journal of Dermatology</i> , 2001 , 144, 751-9	4	34
174	Exogenous topical lactoferrin inhibits allergen-induced Langerhans cell migration and cutaneous inflammation in humans. <i>British Journal of Dermatology</i> , 2001 , 144, 715-25	4	71
173	Cytokine gene polymorphisms in psoriasis. <i>British Journal of Dermatology</i> , 2001 , 144, 849-53	4	66
172	Activation of oral keratinocytes by mercuric chloride: relevance to dental amalgam-induced oral lichenoid reactions. <i>British Journal of Dermatology</i> , 2001 , 144, 1024-32	4	12
171	Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. <i>British Journal of Dermatology</i> , 2001 , 145, 546-53	4	84
170	Patient satisfaction with teledermatology is related to perceived quality of life. <i>British Journal of Dermatology</i> , 2001 , 145, 911-7	4	74
169	The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis. <i>British Journal of Dermatology</i> , 2001 , 145, 1027-8	4	7
168	A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2001 , 145, 886-90	4	62
167	A systematic review of treatments for guttate psoriasis. <i>British Journal of Dermatology</i> , 2001 , 145, 891-44		26
166	Psoriasis 2000: the state-of-the-art today and tomorrow. <i>British Journal of Dermatology</i> , 2001 , 144, 1-1	4	

165	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001 , 144 Suppl 58, 37-43	4	33
164	A 62-year-old man presenting with widespread nodulo-ulcerative cutaneous lesions. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 115-9	1.8	
163	Folliculitis decalvans. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 120-2	1.8	37
162	Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 27-9	1.8	57
161	Psychological influences in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 338-42	1.8	75
160	The role of retinoids in the prevention and repair of aged and photoaged skin. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 613-8	1.8	47
159	Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 648-53	1.8	107
158	A short-term screening protocol, using fibrillin-1 as a reporter molecule, for photoaging repair agents. <i>Journal of Investigative Dermatology</i> , 2001 , 116, 672-8	4.3	55
157	Psoriasis: the future. <i>British Journal of Dermatology</i> , 2001 , 144, 37-43	4	28
156	Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2001 , 145, 438-45	4	111
155	Keeping psoriasis under wraps. <i>Journal of Dermatological Treatment</i> , 2001 , 12, 133	2.8	2
154	Topical tacrolimus in the management of peristomal pyoderma gangrenosum. <i>Journal of Dermatological Treatment</i> , 2001 , 12, 13-7	2.8	76
153	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001 , 44, 643-51	4.5	117
152	Physical and psychologic measures are necessary to assess overall psoriasis severity. <i>Journal of the American Academy of Dermatology</i> , 2001 , 45, 72-6	4.5	134
151	The contribution of perceptions of stigmatisation to disability in patients with psoriasis. <i>Journal of Psychosomatic Research</i> , 2001 , 50, 11-5	4.1	203
150	Patient satisfaction with store-and-forward teledermatology. <i>Journal of Telemedicine and Telecare</i> , 2001 , 7, 45-46	6.8	17
149	Life threatening complications of dermatological therapy. <i>Clinical and Experimental Dermatology</i> , 2001 , 26, 217-218	1.8	
148	Basal cell carcinoma. <i>Cancer</i> , 2000 , 89, 1012-8	6.4	32

147	Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. <i>British Journal of Dermatology</i> , 2000 , 142, 401-12	4	190
146	The Salford Psoriasis Index: an holistic measure of psoriasis severity. <i>British Journal of Dermatology</i> , 2000 , 142, 728-32	4	107
145	Nailfold video capillaroscopy in psoriasis. <i>British Journal of Dermatology</i> , 2000 , 142, 1171-6	4	54
144	'Brooke of Manchester'. <i>British Journal of Dermatology</i> , 2000 , 143, 26-9	4	
143	The spectrum of skin disorders in abdominal stoma patients. <i>British Journal of Dermatology</i> , 2000 , 143, 1248-60	4	142
142	The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. <i>Clinical and Experimental Dermatology</i> , 2000 , 25, 265-8	1.8	13
141	Langerhans cell migration. <i>Clinical and Experimental Dermatology</i> , 2000 , 25, 413-8	1.8	113
140	Topical sucralfate in the management of peristomal skin disease: an open study. <i>Clinical and Experimental Dermatology</i> , 2000 , 25, 584-8	1.8	25
139	Therapeutic strategies for psoriasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2000 , 25, 1-10	2.2	83
138	Mobilization of epidermal langerhans cells - reply from the authors. <i>British Journal of Dermatology</i> , 2000 , 143, 894	4	3
137	Pathological worrying, illness perceptions and disease severity in patients with psoriasis. <i>British Journal of Health Psychology</i> , 2000 , 5, 71-82	8.3	72
136	Investigation of cytomegalovirus and human herpes viruses 6 and 7 as possible causative antigens in psoriasis. <i>Acta Dermato-Venereologica</i> , 2000 , 80, 404-6	2.2	10
135	Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. <i>Archives of Dermatology</i> , 2000 , 136, 1536-43		25
134	Parastomal pyoderma gangrenosum: Clinical features and management. <i>Journal of the American Academy of Dermatology</i> , 2000 , 42, 992-1002	4.5	111
133	Peristomal dermatoses: a novel indication for topical steroid lotions. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 679-82	4.5	48
132	Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol. In the treatment of mild to moderate plaque psoriasis. <i>Pharmacoeconomics</i> , 2000 , 18, 469-76	4.4	14
131	Antistreptococcal interventions for guttate and chronic plaque psoriasis. <i>The Cochrane Library</i> , 2000 , CD001976	5.2	37
130	Interventions for guttate psoriasis. <i>The Cochrane Library</i> , 2000 , CD001213	5.2	12

129	Photoageing 2000 , 437-440		
128	Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. <i>British Journal of Dermatology</i> , 1999 , 140, 562-4	4	33
127	Digital teledermatology for skin tumours: a preliminary assessment using a receiver operating characteristics (ROC) analysis. <i>Journal of Telemedicine and Telecare</i> , 1999 , 5 Suppl 1, S57-8	6.8	31
126	Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. <i>British Journal of Dermatology</i> , 1999 , 141, 185-91	4	181
125	Tumour necrosis factor-alpha induces Langerhans cell migration in humans. <i>British Journal of Dermatology</i> , 1999 , 141, 192-200	4	80
124	Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. <i>British Journal of Dermatology</i> , 1999 , 141, 279-82	4	60
123	Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. <i>British Journal of Dermatology</i> , 1999 , 141, 283-91	4	99
122	Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. <i>British Journal of Dermatology</i> , 1999 , 141, 1054-60	4	152
121	The british association of dermatologists guidelines for the management of skin disease. <i>British Journal of Dermatology</i> , 1999 , 141, 396-7	4	23
120	Dowling Oration delivered at the Royal College of Physicians, London, Friday 5 June 1998. Retinoids: renaissance and reformation. <i>Clinical and Experimental Dermatology</i> , 1999 , 24, 329-35	1.8	6
119	Chronic granulomatous disease and acute neutrophilic dermatosis. <i>Clinical and Experimental Dermatology</i> , 1999 , 24, 368-71	1.8	11
118	Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon?. <i>Clinical and Experimental Dermatology</i> , 1999 , 24, 446-8	1.8	15
117	Fibrillin-rich microfibrils are reduced in photoaged skin. Distribution at the dermal-epidermal junction. <i>Journal of Investigative Dermatology</i> , 1999 , 112, 782-7	4.3	132
116	Drug treatment of photoaged skin. <i>Drugs and Aging</i> , 1999 , 14, 289-301	4.7	19
115	Patients with psoriasis and their compliance with medication. <i>Journal of the American Academy of Dermatology</i> , 1999 , 41, 581-583	4.5	23
114	Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 1116-21	4.3	127
113	Quality of life measures in psoriasis: a critical appraisal of their quality. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998 , 23, 391-8	2.2	50
112	Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. <i>British Journal of Dermatology</i> , 1998 , 138, 77-83	4	77

111	Fibrillin microfibrils are reduced in skin exhibiting striae distensae. <i>British Journal of Dermatology</i> , 1998 , 138, 931-7	4	129
110	Comparison of teleconsultations and face-to-face consultations: preliminary results of a United Kingdom multicentre teledermatology study. <i>British Journal of Dermatology</i> , 1998 , 139, 81-7	4	135
109	All-trans retinoic acid compromises desmosome expression in human epidermis. <i>British Journal of Dermatology</i> , 1998 , 139, 577-84	4	23
108	What patients with psoriasis believe about their condition. <i>Journal of the American Academy of Dermatology</i> , 1998 , 39, 196-201	4.5	120
107	Assessment of topical retinoids for the treatment of Far-East Asian skin. <i>Journal of the American Academy of Dermatology</i> , 1998 , 39, S104-7	4.5	5
106	GMDP and psoriasis. <i>Lancet, The</i> , 1998 , 352, 1857	4.0	1
105	A painful spot on the nose. <i>Lancet, The</i> , 1998 , 351, 566	4.0	1
104	Immunotherapy of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997 , 1, 175-184	1.6	2
103	Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. <i>Journal of Psychosomatic Research</i> , 1997 , 42, 467-75	4.1	94
102	Treatment Options for Photodamaged Skin. <i>Skin Pharmacology and Physiology</i> , 1997 , 10, 1-11	3	1
101	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997 , 137, 344-350	4	20
100	Multiple glomus tumours, Coats' disease and basic fibroblast growth factor. <i>British Journal of Dermatology</i> , 1997 , 137, 454-456	4	5
99	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997 , 137, 755-760	4	53
98	Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. <i>British Journal of Dermatology</i> , 1997 , 137, 755-760	4	137
97	Clinical features of photodamaged human skin are associated with a reduction in collagen VII. <i>British Journal of Dermatology</i> , 1997 , 137, 344-350	4	47
96	Psoriasis, T Cells and Autoimmunity. <i>Journal of the Royal Society of Medicine</i> , 1996 , 89, 315-319	2.3	49
95	A comparison of wire brush and diamond fraise superficial dermabrasion for photoaged skin. A clinical, immunohistologic, and biochemical study. <i>Journal of the American Academy of Dermatology</i> , 1996 , 34, 235-43	4.5	35
94	Topical retinoic acid for photoaged skin: Therapeutic effects and mechanisms. <i>Journal of Dermatological Treatment</i> , 1996 , 7, S23-S27	2.8	2

93	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996 , 134, 431-436	4	1
92	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996 , 135, 60-64	4	16
91	Topical retinoids and cutaneous biology. <i>Clinical and Experimental Dermatology</i> , 1996 , 21, 1-10	1.8	17
90	Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. <i>British Journal of Dermatology</i> , 1996 , 135, 60-64	4	26
89	Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. <i>British Journal of Dermatology</i> , 1996 , 134, 431-436	4	9
88	Topical tretinoin (retinoic acid) improves early stretch marks. <i>Archives of Dermatology</i> , 1996 , 132, 519-526		72
87	Down-regulation of Langerhans cell protein kinase C-beta isoenzyme expression in inflammatory and hyperplastic dermatoses. <i>British Journal of Dermatology</i> , 1995 , 133, 157-67	4	27
86	The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. <i>British Journal of Dermatology</i> , 1995 , 133, 823-9	4	29
85	Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. <i>Journal of Investigative Dermatology</i> , 1995 , 105, 549-56	4.3	240
84	Immunopathogenesis and Immunotherapy of Psoriasis. <i>Dermatologic Clinics</i> , 1995 , 13, 739-749	4.2	27
83	Two Concentrations of Topical Tretinoin (Retinoic Acid) Cause Similar Improvement of Photoaging but Different Degrees of Irritation. <i>Archives of Dermatology</i> , 1995 , 131, 1037		75
82	Retinoic acid antagonizes basal as well as coal tar and glucocorticoid-induced cytochrome P4501A1 expression in human skin. <i>Carcinogenesis</i> , 1995 , 16, 519-24	4.6	18
81	Reduced type I and type III procollagens in photodamaged adult human skin. <i>Journal of Investigative Dermatology</i> , 1995 , 105, 285-90	4.3	297
80	Prolonged occlusion in the treatment of psoriasis: a clinical and immunohistologic study. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 618-22	4.5	29
79	Topical auranofin ointment for the treatment of plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1995 , 33, 517-9	4.5	8
78	A clinical and histologic mycosis fungoides simulant occurring as a T-cell infiltrate coexisting with B-cell leukemia cutis. <i>Journal of the American Academy of Dermatology</i> , 1995 , 33, 341-5	4.5	20
77	Contact dermatitis from topical auranofin. <i>Journal of the American Academy of Dermatology</i> , 1995 , 32, 813-4	4.5	9
76	Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. A double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. <i>Archives of Dermatology</i> , 1995 , 131, 1037-1044		78

75	Efficacy of topical cyclosporin a in the treatment of alopecia areata. <i>Journal of Dermatological Treatment</i> , 1994 , 5, 77-79	2.8	3
74	Cutaneous Leukocyte Trafficking and Psoriasis. <i>Archives of Dermatology</i> , 1994 , 130, 494		18
73	Human in vivo pharmacology of topical retinoids. <i>Archives of Dermatological Research</i> , 1994 , 287, 53-60	3.3	22
72	Topical tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: a vehicle-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 1994 , 30, 76-84	4.5	78
71	Cutaneous leukocyte trafficking and psoriasis. <i>Archives of Dermatology</i> , 1994 , 130, 494-499		23
70	Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. <i>Archives of Dermatology</i> , 1994 , 130, 727-733		219
69	Clinical improvement following dermabrasion of photoaged skin correlates with synthesis of collagen I. <i>Archives of Dermatology</i> , 1994 , 130, 1136-1142		48
68	CD1 gene expression in human skin. <i>Journal of Dermatological Science</i> , 1993 , 6, 206-13	4.3	17
67	Effect of tretinoin on collagen formation in photodamaged skin. <i>New England Journal of Medicine</i> , 1993 , 329, 2038; author reply 2038-9	59.2	
66	Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). <i>New England Journal of Medicine</i> , 1993 , 329, 530-5	59.2	401
65	Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. <i>New England Journal of Medicine</i> , 1993 , 328, 1438-43	59.2	162
64	Tretinoin for hyperpigmentation in black patients. <i>New England Journal of Medicine</i> , 1993 , 329, 1503	59.2	6
63	Topical retinoic acid for photoaging: clinical response and underlying mechanisms. <i>Skin Pharmacology and Physiology</i> , 1993 , 6 Suppl 1, 70-7	3	29
62	Curly lusterless hair: anatomic surface changes on transplanted hair shafts. <i>The Journal of Dermatologic Surgery and Oncology</i> , 1993 , 19, 1129-30		5
61	Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. <i>Journal of Investigative Dermatology</i> , 1993 , 101, 325-8	4.3	33
60	Differential expression of protein kinase C isoenzymes in normal and psoriatic adult human skin: reduced expression of protein kinase C-beta II in psoriasis. <i>Journal of Investigative Dermatology</i> , 1993 , 101, 553-9	4.3	73
59	Stimulus-selective induction of CRABP-II mRNA: a marker for retinoic acid action in human skin. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 356-9	4.3	57
58	Differential regulation of tyrosinase activity in skin of white and black individuals in vivo by topical retinoic acid. <i>Journal of Investigative Dermatology</i> , 1993 , 100, 800-5	4.3	31

57	An in vivo experimental model for effects of topical retinoic acid in human skin. <i>British Journal of Dermatology</i> , 1993 , 129, 389-94	4	72
56	Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. <i>British Journal of Dermatology</i> , 1993 , 129, 415-21	4	197
55	Inflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosis. <i>British Journal of Dermatology</i> , 1993 , 129, 324-6	4	19
54	Paraneoplastic pemphigus presenting as a lichen planus pemphigoides-like eruption. <i>Archives of Dermatology</i> , 1993 , 129, 866-869		74
53	Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. <i>New England Journal of Medicine</i> , 1992 , 326, 368-74	59.2	147
52	A Photonumeric Scale for the Assessment of Cutaneous Photodamage. <i>Archives of Dermatology</i> , 1992 , 128, 347		124
51	Psoriasis. I. Pathogenesis. <i>Journal of the American Academy of Dermatology</i> , 1992 , 27, 98-101	4.5	6
50	Failure of reticular erythematous mucinosis to respond to cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 1992 , 27, 825-8	4.5	37
49	Immunological mechanisms involved in psoriasis. <i>Seminars in Immunopathology</i> , 1992 , 13, 441-54		18
48	Differential modulation of transforming growth factor-beta 1 expression and mucin deposition by retinoic acid and sodium lauryl sulfate in human skin. <i>Journal of Investigative Dermatology</i> , 1992 , 98, 1024-8	4.3	49
47	Acute or chronic topical retinoic acid treatment of human skin in vivo alters the expression of epidermal transglutaminase, loricrin, involucrin, filaggrin, and keratins 6 and 13 but not keratins 1, 10, and 14. <i>Journal of Investigative Dermatology</i> , 1992 , 98, 343-50	4.3	98
46	Short-term retinoic acid treatment increases in vivo, but decreases in vitro, epidermal transglutaminase-K enzyme activity and immunoreactivity. <i>Journal of Investigative Dermatology</i> , 1992 , 99, 283-8	4.3	24
45	Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. <i>Journal of Investigative Dermatology</i> , 1992 , 99, 343-9	4.3	158
44	Cellular localization of mRNA for cellular retinoic acid-binding protein II and nuclear retinoic acid receptor-gamma 1 in retinoic acid-treated human skin. <i>Journal of Investigative Dermatology</i> , 1992 , 99, 146-50	4.3	34
43	Mechanisms of action of retinoic acid in skin repair. <i>British Journal of Dermatology</i> , 1992 , 127 Suppl 41, 21-4	4	8
42	The clinical identification and quantification of photodamage. <i>British Journal of Dermatology</i> , 1992 , 127 Suppl 41, 37-42	4	82
41	Differential regulation of retinoic acid receptors and binding proteins in human skin. <i>Journal of Investigative Dermatology</i> , 1992 , 98, 673-9	4.3	101
40	A photonumeric scale for the assessment of cutaneous photodamage. <i>Archives of Dermatology</i> , 1992 , 128, 347-351		128

39	Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. <i>Archives of Dermatology</i> , 1992 , 128, 786-90		25
38	Treatment of pyoderma gangrenosum with cyclosporine. <i>Archives of Dermatology</i> , 1992 , 128, 1060-1064		125
37	Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-alpha) in allergic contact dermatitis (rhus dermatitis). <i>British Journal of Dermatology</i> , 1991 , 124, 519-26	4	144
36	Aberrant intercellular adhesion molecule-1 (ICAM-1) expression by hair-follicle epithelial cells and endothelial leukocyte adhesion molecule-1 (ELAM-1) by vascular cells are important adhesion-molecule alterations in alopecia areata. <i>Journal of Investigative Dermatology</i> , 1991 , 96, 91S-92S	4.3	27
35	Induction of proliferation of growth-inhibited keratinocytes and fibroblasts in monolayer culture by sodium lauryl sulfate: comparison with all-trans retinoic acid. <i>Journal of Investigative Dermatology</i> , 1991 , 97, 917-21	4.3	27
34	Keratinocytes as initiators of inflammation. <i>Lancet, The</i> , 1991 , 337, 211-4	4.0	649
33	A Review and Update of the Clinical Uses of Cyclosporine in Dermatology. <i>Dermatologic Clinics</i> , 1991 , 9, 805-817	4.2	29
32	Differential modulation of keratinocyte intercellular adhesion molecule-I expression by gamma interferon and phorbol ester: evidence for involvement of protein kinase C signal transduction. <i>British Journal of Dermatology</i> , 1990 , 122, 333-42	4	79
31	Not all spindled-shaped cells embedded in a collagenous stroma are fibroblasts: recognition of the "collagen-associated dendrophage". <i>Journal of Cutaneous Pathology</i> , 1990 , 17, 252-4	1.7	19
30	Phosphoinositide-mediated signal transduction in normal and psoriatic epidermis. <i>Journal of Investigative Dermatology</i> , 1990 , 95, 15S-17S	4.3	18
29	Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. <i>Journal of Investigative Dermatology</i> , 1990 , 95, 35S-37S	4.3	44
28	Cyclophilin content of normal and psoriatic epidermis. <i>Journal of Investigative Dermatology</i> , 1990 , 94, 436-40	4.3	11
27	Abnormal cutaneous topobiology: the molecular basis for dermatopathologic mononuclear cell patterns in inflammatory skin disease. <i>Journal of Investigative Dermatology</i> , 1990 , 95, 128S-131S	4.3	18
26	The role of adhesion molecules, chemotactic factors, and cytokines in inflammatory and neoplastic skin disease--1990 update. <i>Journal of Investigative Dermatology</i> , 1990 , 94, 151S-157S	4.3	181
25	Systemic and local administration of cyclosporine in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 1990 , 23, 1242-6; discussion 1246-7	4.5	21
24	Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. <i>Journal of the American Academy of Dermatology</i> , 1990 , 22, 242-50	4.5	158
23	Constitutive absence and interferon-gamma-induced expression of adhesion molecules in basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 1990 , 22, 721-6	4.5	26
22	Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study. <i>Journal of the American Academy of Dermatology</i> , 1990 , 22, 94-100	4.5	87

21	Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. <i>New England Journal of Medicine</i> , 1990 , 323, 290-4	59.2	176
20	Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. <i>Archives of Dermatology</i> , 1990 , 126, 339-350		133
19	Sulfasalazine improves psoriasis. A double-blind analysis. <i>Archives of Dermatology</i> , 1990 , 126, 487-493		59
18	Long-term cyclosporin for psoriasis. <i>British Journal of Dermatology</i> , 1989 , 120, 253-60	4	66
17	Gamma interferon induces different keratinocyte cellular patterns of expression of HLA-DR and DQ and intercellular adhesion molecule-1 (ICAM-1) antigens. <i>British Journal of Dermatology</i> , 1989 , 120, 1-8	4	90
16	Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. <i>British Journal of Dermatology</i> , 1989 , 121, 421-31	4	314
15	Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. <i>Journal of the American Academy of Dermatology</i> , 1989 , 20, 617-29	4.5	458
14	(25) Long-term follow-up of low-dose cyclosporin treatment for psoriasis. <i>British Journal of Dermatology</i> , 1988 , 119, 56-57	4	
13	Cyclosporin A does not inhibit epidermal growth at therapeutic levels. <i>Journal of Investigative Dermatology</i> , 1988 , 90, 536	4.3	
12	Topical cyclosporin and psoriasis. <i>Lancet, The</i> , 1987 , 1, 806	4.0	49
11	Gliadins bind to reticulin in a lectin-like manner. <i>Archives of Dermatological Research</i> , 1987 , 279, 232-5	3.3	10
10	The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. <i>British Journal of Dermatology</i> , 1987 , 116, 503-10	4	131
9	Exacerbation of psoriasis by indomethacin. <i>British Journal of Dermatology</i> , 1987 , 117, 799-800	4	32
8	(8) Comparison of psoriasis treated with cyclosporin alone or cyclosporin and clobetasol propionate. <i>British Journal of Dermatology</i> , 1987 , 117, 35-36	4	2
7	(11) Oesophageal strictures in cicatricial pemphigoid. <i>British Journal of Dermatology</i> , 1987 , 117, 37-37	4	1
6	PSORIASIS AND INTERFERON. <i>Lancet, The</i> , 1986 , 328, 342-343	4.0	5
5	Psoriasis. <i>British Medical Journal</i> , 1986 , 293, 266		2
4	IgA anti-endomysial antibody detection in the serum of patients with dermatitis herpetiformis following gluten challenge. <i>Archives of Dermatological Research</i> , 1985 , 277, 349-51	3.3	24

- 3 The effects of topical treatment with steroids or dithranol on epidermal T lymphocytes and dendritic cells in psoriasis. *Scandinavian Journal of Immunology*, **1985**, 22, 471-7 3.4 30
- 2 Peptide location fingerprinting reveals modification-associated biomarkers of ageing in human tissue proteomes 1
- 1 Photoaging326-336